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Bioflavonoids represent a class of naturally
occurring plant pigments that humans con-
sume daily in gram quantities (1,2). A high
correlation exists between the intake of
bioflavonoid-rich diets and a lower inci-
dence of stomach, colon, breast, and
prostate cancer in man (3-7). For these rea-
sons, some investigators have suggested that
consumption of weakly estrogenic
isoflavonoids such as equol, daidzein, and
coumestrol may prevent estrogen-depen-
dent breast and prostate cancers by compet-
ing with more active, endogenous estrogens
such as estradiol for estrogen receptor (ER)
in these target tissues (5-7). Conversely,
studies by our laboratory and others have
shown that flavonoids such as luteolin and
quercetin bind with high affinity (Kd 1-5
nM) to nuclear type II [3H]estradiol bind-
ing sites, but not ER, and this is correlated
with the antagonism ofestrogenic response
in the rat uterus, the inhibition of breast,
ovarian, pancreatic, and colon cancer cell
proliferation in vitro and estrogen-indepen-
dent mammary tumor growth in mice
(8-13). Therefore, it is not surprising that a
naturally occurring flavonoid metabolite,
methyl p-hydroxyphenyllactate (MeHPLA),
has been identified as an endogenous cell-
growth-regulating agent and the natural lig-
and for the type II site (14). On the basis of
these studies demonstrating mixed
agonist/antagonist (estrogenic/antiestro-
genic) activities of flavonoids and
isoflavonoids in estrogen-responsive tissues,
it is likely that dietarily derived flavonoids
and/or their metabolites which interact
either with ER or type II sites may pro-
foundlyaffect reproductive function and the
incidence ofestrogen-dependent breast and
prostate cancer (3-.
Although isoflavonoids such as coume-
strol have demonstrated estrogenic activity
in avariety ofexperimental systems, most of
these studies involved feeding these com-
pounds to intact animals for periods oftime
ranging from days to weeks and subsequent-
ly determining uterine wet and/or dry
weights (15-19). Consequently, the
uterotropic response profiles to phytoestro-
gens have not been extensively evaluated in
ovariectomized animals, in which the con-
tribution of ovarian steroids to the overall
net uterine hypertrophy, hyperplasia, and
DNA synthesis has been eliminated. Recent
studies have shown that oral administration
ofcoumestrol to intact, immature rats failed
to antagonize estrogenic stimulation of
uterine growth, and, in fact, coumestrol
treatment increased uterine weight in these
studies, suggesting that this isoflavonoid
possessed estrogenic activity (15-17).
However, because these studies involved the
treatment of intact, immature female mice
with coumestrol over a period ofdays, it is
possible that coumestrol modulated
gonadotropin secretion and/or ovarian
steroidogenesis, which may have been par-
tially responsible for the observed estrogenic
response. A recent report by Yamazaki (20)
demonstrating that the isoflavonoid ipri-
flavone is estrogenic in intact, but not
ovariectomized, immature rats also supports
this hypothesis (20).
Our studies described here were
designed to assess the estrogenic activity of
parenterally and orally administered
coumestrol in the immature, ovariec-
tomized rat to rule out the effects ofovari-
an estrogen on uterotropic response pat-
terns. These data demonstrate that at the
dose levels and treatment conditions used,
coumestrol behaved as an atypical estrogen,
failing to cause significant cytosolic-deple-
tion and nuclear accumulation of ER or
uterine hyperplasia and DNA synthesis in
the ovariectomized rat, even though uterine
wet and dry weights were elevated above
control levels. Therefore, the true estro-
genic activity of coumestrol, and perhaps
other well-known phytoestrogens, requires
careful evaluation in ovariectomized ani-
mals, particularly in view of the fact that
emphasis is currently being directed toward
defining the relationships between phytoe-
strogen exposure and neoplasia in estrogen-
responsive tissues such as the mammary
gland, uterine endometrium, and prostate.
Materials and Methods
Chemicals. Coumestrol was purchased
from Eastman Kodak (Rochester, New
York) and genestein and daidzein were
purchased from Indofine (Somerville, New
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Jersey). The purity of the flavonoids was
determined to be greater than 99% by
HPLC analysis using a pBondapak CH8
column (Waters/Millipore, Milford,
Massachusetts) eluted with water:methanol
by standard procedures in our laboratory
(9). Estradiol and diethylstilbestrol were
obtained from Sigma (St. Louis, Missouri)
and 2, 4, 6, 7-[3H]estradiol (112 Ci/
mmole) was purchased from Amersham
Radiochemicals (Boston, Massachusetts).
Animals andtreatment. Immature (21-
day-old) Sprague-Dawley female rats
(Holtzman Laboratories, Madison,
Wisconsin) were ovariectomized under
Metofane anesthesia by standard proce-
dures and allowed to recover 7-10 days
before treatment. Animals were housed in
stainless-steel cages under controlled con-
ditions consisting of 12 hr of light daily
(lights on at 0700 hr), and food and water
were provided ad libitum. We separated
the rats into treatment groups consisting of
five or six animals per group and injected
them subcutaneously or treated them oral-
ly with the indicated dose levels ofestradi-
ol or coumestrol dissolved in saline-2.0%
Tween 80 (injection) or tap water-2.0%
Tween 80 vehicle (oral dosing studies)
under the conditions described in the text
and figure legends. This method of oral
administration is remarkably consistent
throughout the treatment period, and phy-
toestrogens were delivered for weeks with-
out significant effects on body weights or
other signs ofgeneralized, nonspecific sys-
temic cytotoxicity. In these experiments,
the 30- to 40-day-old rats typically con-
sumed 25.8 ± 4.4 mL ofvehicle or coume-
strol solution per day. At a concentration
of 50 pg coumestrol/mL of tap water-
Tween-80 vehicle, this represented a dose
of 1.29 ± 0.22 mg of coumestrol per day
per animal and doses in excess of -13
mg/rat/day (500 pg/mL drinking water;
-286 mg/kg body weight) can be readily
delivered by this procedure. Animals were
sacrificed by cervical dislocation and the
uteri were removed, stripped ofextraneous
tissue, weighed, and stored in saline at 40C
for biochemical analysis. To obtain dry
weights, uteri from some of the animals
(five to six per treatment group) were dried
in an oven at 70°C for 16-24 hr until con-
stant weights were obtained.
Tissue homogenization andfractiona-
tion. For biochemical analyses, we homog-
enized uteri from the control and treated
animals in ice-cold TE buffer (10 mM
Tris, 1.5 mM EDTA, pH 7.4 at 22°C) in
Kontes ground-glass homogenizers in a
volume equivalent to 100 mg fresh uterine
wet weight equivalents per milliliter and
centrifuged the homogenate at 800gfor 20
min in a Beckman GH-3 rotor to obtain
the low-speed cytosol (supernatant) and
nuclear pellet fractions (21,22). The
cytosol was centrifuged at 40,000g for 30
min in a Beckman JA 20 rotor to obtain
the high-speed cytosol fraction, and equiv-
alent results are routinely obtained with
200,000g cytosol preparations. We washed
the nuclear pellet fraction three times by
resuspension and centrifugation (800g for
7 min) in TE buffer before resuspension in
the same buffer and analysis for ER or type
II sites by [3H]estradiol exchange as
described below.
Measurement ofcytosolic and nuclear
ER by [3H]estradiol exchange. We diluted
cytosol and nuclear fractions from control
and treated animals to 20 mg fresh uterine
wet weight equivalents/mL in TE buffer
and brought them to 10 mM with dithio-
threitol (21,22). The preparations were
incubated at 40C for 140 min in the pres-
ence of the reducing agent to eliminate
interference from type II sites (21,22).
Aliquots (250 pL) ofthe cytosol or nuclear
suspensions were incubated (cytosol, 300C
for 30 min; nuclei, 300C for 30 min) in the
presence of a wide range of [3H]estradiol
concentrations (0.4 to 10 nM, total bind-
ing) ± 300-fold excess diethylstilbestrol
(0.12-3.0 pM, nonspecific binding). After
this incubation, we incubated cytosol frac-
tions (40C for 15 min) with hydroxylapetite
(HAP) and washed the HAP bound protein
by resuspension and centrifugation (800g
for 5 min) to separate bound and free
[3H]estradiol. Nuclear suspensions were also
washed by resuspension and centrifugation
to remove free [3H]estradiol (21,22). Bound
[3H]estradiol was extracted from the final,
washed HAP or nuclear pellets with ethanol
and specific [3H]estradiol binding evaluated
by Scatchard analysis (21,22). Results were
expressed as ER sites per cell assuming that
mammalian tissues contain approximately 7
pg of DNA per cell nucleus (23). Uterine
DNA content was estimated by the method
ofBurton (24).
In studies where the binding affinity of
the various phytoestrogens for ER was
assessed, uterine cytosol fractions from
ovariectomized rats were prepared exactly
as described above and diluted to 20
mg/mL in TE buffer containing 10 mM
dithiothreitol. After preincubation (140
min at 40C) in the presence of reducing
agent to eliminate interference from
cytosol type II sites (21), aliquots of the
cytosol were incubated (370C for 30 min)
in triplicate in the presence of 10 nM
[3H]estradiol ± the indicated concentra-
tions (0.1 nM-10.0 pM) of daidzein,
genistein, coumestrol, or diethylstilbestrol,
and bound and free steroid were separated
by HAP adsorption as described above. We
determined [3H]estradiol binding to ER in
these studies in the absence (100% bound)
or presence ofthe competitor as previously
described (8). In a typical experiment,
100% bound represented approximately
5000 cpm.
Assessment ofisoflavonoid binding
affinityfor nuclear type II sites. Since
nuclear type II site stimulation appears to
be involved in target cell response to estro-
genic hormones, and flavonoids such as
luteolin, quercetin, and pelargonidin
appear to inhibit cellular proliferation
through type II site binding interactions
(8), we determined the binding affinities of
isoflavonoids such as coumestrol, daidzein,
and genistein for type II sites in rat uterine
nuclei. For these studies, uterine nuclear
fractions from estradiol-implanted rats (8)
were prepared in TE buffer, diluted to a
final volume equivalent to 20 mg uterine
wet weight equivalents/mL, and incubated
(40C for 60 minutes) in the presence of20
nM [3H]estradiol ± the indicated concen-
trations of competitor (1.0 nM-20.0 pM)
as described in the figure legends. After
incubation, the nuclear suspensions were
washed by resuspension in TE buffer and
centrifugRation to remove free steroid, and
bound [ H]estradiol was determined by
liquid scintillation counting exactly as pre-
viously described (8). A value of 100%
bound in the absence ofcompetitor repre-
sented approximately 25, 000 cpm.
Measurement ofcytosolic and nuclear
type II sites by [3H estradiol exchange. In
experiments where it was necessary to
quantitate treatment effects on the levels of
cytosolic and nuclear type II binding sites,
these subcellular fractions were prepared
exactly as described above for the type II
site competition assays (21,22). We quan-
tified cytosolic type II sites by saturation
analysis using the hydroxylapetite adsorp-
tion-[3H]estradiol exchange assay
(HAA-[3H]estradiol exchange) previously
developed by our laboratory for measure-
ment of type II sites without interference
from endogenous ligands such as
MeHPLA (22,25). Briefly, cytosol prepara-
tions from controls and coumestrol-treated
animals were incubated with hydroxyl-
apetite (HAP) at 40C for 15 min to allow
the type II site to bind to the HAP. The
pellet bound protein was washed three
times by resuspension in TE buffer and
centrifugation (800g for 7 min), and the
final washed pellet was resuspended in TE
buffer and aliquots incubated (220C for 16
hr) in the presence of a wide range (0.4
nM-40 nM) of [3H]estradiol concentra-
tions in the absence (total binding) or pres-
ence (nonspecific binding) of 300-fold
excess diethylstilbestrol (22,25). Similarly,
the washed nuclear pellet fractions from
these uteri were incubated (40C for 60
min) with [3H]estradiol ± diethylstilbes-
trol, and specific binding to type II sites in
cytosol and nuclear fractions was deter-
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tent (sites/cell) as previously described in
detail (23). DNA was estimated by the
method ofBurton (24).
Statistical analyses. Where indicated,
the experimental results are expressed as
the mean ± SEM. The data presented in
the various figures in this manuscript were
analyzed statistically by the appropriate
one-way or two-way analysis of variance
(fixed treatment models) and Duncan's
new multiple range test on the treatment
means as described in detail (26).
Results
To correlate phytoestrogen binding interac-
tions with biological response, we evaluated
the binding affinities of these compounds
with ER and type II sites in rat uterine
nuclear fractions. The data in Figure 1
demonstrate that coumestrol (Kd -180
nM), daidzein (Kd >1000 nM), and genis-
tein (Kd -180 nM) bind to the ER (Fig.
IA) with relatively low affinities as
described by numerous laboratories for var-
ious tissues (16,26). This is consistent with
the fact that these compounds are weak or
short-acting estrogens with substantially less
biological activity than long-acting estrogens
such as estradiol (28). Coumestrol (Kd -10
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Figure 1. Bioflavonoid competition for (A) estro-
gen receptor (ER) and (B) type 11 binding sites in
rat uterine cytosol and nuclei. Uterine cytosol and
nuclear fractions were incubated in the presence
of [3Hlestradiol (10 nM, ER; 20 nM, type 11) plus or
minus the indicated concentrations of competitor
under conditions optimum for each ofthe respec-
tive binding sites as described in methods. DES,
diethylstilbestrol.
nM), daidzein (Kd -5 nM), and genistein
(Kd -5 nM) displayed higher binding affini-
ties for type II sites than for the ER (Fig. 1),
and the apparent binding affinities of these
three isoflavonoids for nuclear type II sites
are similar to those determined for luteolin
and quercetin, which bind to nuclear type II
sites (but not ER) with very high affinity
(Ad -1-5 nM) and inhibit estrogen stimula-
tion ofuterine growth in the rat and mam-
mary tumor growth in the mouse (8,9).
Because coumestrol displayed higher
affinity for ER than daidzein and has
recently been described as an estrogen in
the intact, immature female rat, we focused
our efforts on the characterization of the
estrogenic activity of coumestrol in the
immature, ovariectomized rat uterine
model system. Dose-response studies
demonstrated that a single injection of
coumestrol in doses ranging from 50 to
200 pg resulted in a significant increase in
uterine wet weight relative to control (Fig.
2), and the response obtained with
100-200 pg of coumestrol was equivalent
to that obtained after a single injection of 1
pg estradiol-17f9. Therefore, it appeared
that in the immature, ovariectomized rat,
coumestrol treatment increased uterine wet
weight 24 hr after a single injection in a
manner similar to that described for long-
acting estrogens such as estradiol (28,29).
The data in Figure 3 represent the tem-
poral effects of coumestrol on uterine wet
weight and DNA content after the injec-
tion of 100 pg of this phytoestrogen. As
expected, based on previous studies sug-
gesting that coumestrol has estrogenic
activity (15-1/), uterine wet weight was
increased within 4 hr after coumestrol
treatment, and this response was sustained
for 24 hr, declining to control levels by 62
hr after injection. This observation was
consistent with that reported for active
estrogens such as estradiol, where sustain-
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Figure 2. Effects of coumestrol and estradiol on
uterine growth. Immature, ovariectomized rats
received a single subcutaneous injection of vehi-
cle (controls) or the indicated concentrations of
estradiol or coumestrol. Uterine wet weights were
dee rmi.ne ,4 hr
- after InMecto ( No great
response was subsequently obtained with a single
subcutaneous injection of 500 pg coumestrol. Data
are means ± SEM.
ing uterine wet weight beyond 24 hr after
injection is typically associated with the
stimulation of cellular DNA synthesis and
true uterine growth (29). Much to our sur-
prise, even though coumestrol treatment
increased uterine wet and dry weights in a
manner similar to that obtained with estra-
diol, it failed to increase uterine DNA con-
tent at 24 hr after injection. These findings
suggest that in the immature, ovariec-
tomized rat, coumestrol behaves as an
atypical estrogen, which stimulates cellular
hypertrophy and perhaps protein synthesis
without stimulating cellular hyperplasia,
reflected by a doubling in DNA content
(29). Therefore, coumestrol mimics estriol,
estrone, and estradiol-17ct in this model
system by behaving as a short-acting estro-
gen, capable of stimulating cellular hyper-
trophy and not hyperplasia when adminis-
tered as a single injection (28-31).
We also assessed the effects ofmultiple
injections of this phytoestrogen on uterine
wet weight and DNA content 24 hr after
the last injection (Fig. 4) because estriol
and estradiol-17(x have been shown to
stimulate uterine cellular hypertrophy and
hyperplasia in the intact immature (29) or
adult-ovariectomized (28,30,31) rats when
administered by multiple injection or pel-
let implant. Therefore, we expected that
similar results would be obtained after
multiple injections ofcoumestrol. The data
in Figure 4 clearly demonstrate that this
was not the case. Although multiple injec-
tions of coumestrol increased uterine wet
weight relative to control, this response
was not equivalent to that after following a
single injection of 1 pg estradiol (Fig. 4A).
More importantly, estradiol treatment
nearly doubled uterine DNA content (Fig.
4B), whereas neither single or multiple
injections of this phytoestrogen increased
uterine DNA content in this study. In fact,
two injections of coumestrol may have
slightly reduced uterine DNA content rela-
tive to control (Fig. 4B). These data fur-
ther confirm that in the immature, ovariec-
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Figure 3. Temporal effects of coumestrol on uter-
ine growth. Ovariectomized rats (four to six per
group) were injected with vehicle (controls) or
coumestrol (100 pg), and uterine wetweights and
DNA content were determined at the indicated
times following treatment. The data represent the
means fortwo separate experiments.
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tomized rat, coumestrol behaves as an
atypical estrogen.
To explain the inability of coumestrol
to stimulate uterine cellular hyperplasia
(increased uterine DNA content) in the
ovariectomized rat, we assessed the effects
of this isoflavonoid on the intracellular
compartmentalization of ER in the uterus
at various times after treatment. Although
it is likely that ER is localized in the nucle-
us and cytosolic ER is most likely an arti-
fact generated during tissue homogeniza-
tion (32-34), the assessment of ER
dynamics (cytosolic ER depletion and
nuclear ER accumulation) after estrogen
administration can be used to assess the
estrogenicity of a variety of compounds
(29,34). In the present studies, we injected
immature, ovariectomized rats with a dose
(100 pg) ofcoumestrol, which substantial-
ly increased uterine wet weight without
causing cellular hyperplasia (Fig. 4) and
the levels ofcytosolic and nuclear ER were
measured as a function of time after treat-
ment (Fig. 5). Again, coumestrol behaved
as an atypical estrogen, failing to cause
measurable cytosolic ER depletion or sig-
nificant nuclear ER accumulation. In fact,
cytosolic ER levels were elevated above the
time zero control level within 4 hr after
coumestrol treatment and reached a maxi-
mum two- to threefold induction by24 hr.
To ensure that the atypical effects of
coumestrol on ER dynamics were not a
characteristic of the model system, we
compared the temporal effects of estradiol
and couumestrol on ER compartmentaliza-
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tion in the rat uterus in immature, ovariec-
tomized rats. The data in Figure 6 clearly
demonstrate that the cytosolic ER deple-
tion and nuclear ER retention patterns
after estradiol injection were exactly as
described by our laboratory and others for
the rat uterine model system under a vari-
ety of experimental conditions (29,35-41)
and the level ofcytosolic ERdid not return
to control levels (0 hours) until 16-24 hr
after treatment. It is this sustained cytoso-
lic ER depletion and nuclear ER occupan-
cy that correlates with estrogenic stimula-
tion ofcellular hyperplasia and DNA syn-
thesis (28,29). The failure ofcoumestrol to
mimic these ER dynamics is likely respon-
sible for the inability ofthis phytoestrogen
to stimulate DNA synthesis in these stud-
ies. However, again, in this second experi-
ment, coumestrol treatment did not cause
cytosolic depletion or nuclear ER accumu-
lation/retention even though cytosolic ER
levels were elevated two- to threefold above
time zero controls by 24 hr.
The aforementioned experiments sug-
gested that coumestrol was an atypical
estrogen when administered subcutaneous-
ly. Therefore, we evaluated the sustained
effects of this compound on uterine
growth in the rat after oral administration
in the drinking water. These studies
demonstrated that 96 hr after treatment,
orally administered coumestrol resulted in
a dose-dependent increase in uterine wet
and dry weight relative to controls at dose
levels ranging from 5 to 100 pg/mL.
Uterine wet and dryweights were essential-
ly doubled by treatment with 100 pg of
coumestrol/mL drinking water (-60 mg/kg
body weight/day; Fig. 7). Time studies
with the higher dose level of coumestrol
(100 pg/mL drinking water) demonstrated
that the uterotropic response peaked
between 72 and 96 hr after treatment, and
uterine wet and dry weights were increased
20,000 LUMMuiuiOl
five- to sixfold relative to the time-zero
vehicle controls (Fig. 8). More important,
however, was the observation that uterine
DNA content 72 hr after coumestrol treat-
ment (242 pg/uterus) was nearly equiva-
lent to the control value (217 pg/uterus),
suggesting that coumestrol failed to stimu-
late significant cellular hyperplasia and
DNA synthesis even when administered in
a sustained fashion under these experimen-
tal conditions.
To further characterize the uterotropic
response patterns to orally administered
coumestrol, we also assessed the effects of
this phytoestrogen on cytosolic and nuclear
ER and nuclear type II binding site levels
72 hr after oral administration (Fig. 9).
These data essentially confirmed the injec-
tion studies (Figs. 5 and 6) in that oral
administration of coumestrol also failed to
cause accumulation of nuclear ER or
deplete cytosolic ER. In fact, coumestrol
treatment resulted in a three- to fourfold
induction in the level of cytosolic ER, as
was the case for the coumestrol injection
studies. That nuclear type II sites were not
stimulated by coumestrol treatment (Fig. 9)
is consistent with the observation that uter-
ine hyperplasia and DNA synthesis was not
stimulated by coumestrol under these con-
ditions (see legend to Figure 8). Estrogen
stimulation of nuclear type II sites in the
rat uterus is directly correlated with the
induction ofuterine cellular DNAsynthesis
and true uterine growth under a wide vari-
ety ofexperimental conditions (28-30,35).
That cytosolic type II sites appeared to be
slightly increased following coumestrol
treatment (Fig. 8) is interesting; however,
the relationship between this soluble
[3H]estradiol binding site and uterotropic
Control 1x
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Figure 4. Effects of multiple coumestrol injections
on uterine growth in the rat. Ovariectomized rats
received one daily injection of 10 pg estradiol or
one or two daily injections of 100 pg coumestrol
as indicated. Controls were injected with 2%
Tween 80 in 0.9% saline vehicle. (A) Uterine wet
weights and (B) DNA content were determined 24
hr afterthe last injection. Data are means ± SEM.
0 20 40 60 80
HoursafterInjection
Figure 5. Effects of coumestrol on rat uterine
estrogen receptor (ER) dynamics. Ovariectomized
rats were injected subcutaneously with 100 pg
coumestrol or vehicle (time 0 controls) and uterine
cytosol and nuclear estrogen receptors were
assayed by [3H]estradiol exchange. Results are
expressed as sites per cell (23). Data are means +
SEM.
10,000
5,000
HoursafterInjection
Figure 6. Effects of estradiol and coumestrol on
estrogen receptor (ER) dynamics in the rat uterus.
Ovariectomized rats received a single injection of
estradiol (5 pg) or coumestrol (100 pg), and estro-
gen receptors (ER) were measured in cytosol and
nuclear fractions by [3H]estradiol exchange at the
indicated times after injection. Results were
based on DNA content and were expressed as
sites/cell as described. In separate experiments
essentially identical ER responses were observed
following a 500 pg injection of coumestrol.
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Figure 7. Dose response of rat uterus to coumestrol. Ovariectomized rats were given the indicated con-
centrations of coumestrol dissolved in drinking water containing 2% Tween 80. Controls received water
or the 2% Tween-80 vehicle and uterine wet and dry weights were determined 96 hr after treatment.
Data are means ± SEM.
response has not been evaluated.
On the basis of the aforementioned
studies demonstrating that coumestrol
treatment will stimulate cytosolic ER levels
in the rat uterus (Figs. 5, 6, and 9), we sus-
pected that subcutaneous or oral exposure
to this phytoestrogen may alter the
uterotropic response to estrogenic steroids.
To evaluate this possibility, immature,
ovariectomized rats were treated orally
with vehicle (controls) or coumestrol (250
pg/mL) for 5 days before receiving three
daily subcutaneous injections of various
doses ofestradiol (0.01-10 pg) and uterine
weight was determined 24 hr after the last
injection. Coumestrol pretreatment
increased uterine sensitivity to estradiol as
the response of the coumestrol pretreated
uterus to doses ofestradiol greater than 0.1
pg/day was significantly (p <0.05) greater
than that observed in the vehicle pretreated
controls. Therefore, coumestrol induction
of ER during the 5-day pretreatment peri-
od significantly enhanced uterine sensitivi-
ty to estradiol.
Discussion
A major focus of our laboratory over the
past decade has been estrogen regulation of
normal and abnormal cell growth and pro-
liferation. Our efforts have led to the iden-
tification of a bioflavonoid metabolite
(MeHPLA) as an important cell growth
regulating agent (9,14). MeHPLA is an
endogenous ligand for nuclear type II sites
(14), and occupancy of this site by
MeHPLA and bioflavonoids such as lute-
olin and quercetin appears to inhibit estro-
gen stimulation of uterine growth in the
rat and mammary tumor growth in mice
(8,9,14). Subsequent studies demonstrate a
direct correlation exists between the occu-
pancy of type II sites by flavonoids such as
luteolin, quercetin, and dihydroxybenzyli-
dine acetophenone and the inhibition of
breast (8-10), colorectal (11), pancreatic
(12, and ovarian cancer (13) as well as the
inhibition of leukemia (42) and lym-
phoblastoid cell proliferation (43). These
bioflavonoids do not bind to the ER (8),
suggesting that the antiestrogenic and/or
inhibitory effects of these compounds on
cellular proliferation are mediated through
type II sites. Therefore, it is likely that
dietarily derived bioflavonoids inhibit nor-
mal and abnormal cell growth through this
mechanism as well.
Conversely, isoflavonoids such as
coumestrol, genistein, and daidzein have
been described as estrogens, antiestrogens,
and anticarcinogens because of their abili-
ties to bind to ER in estrogen target cells
(44-48), even though these compounds
inhibit the proliferation of ER negative
breast cancer cells (49). This former
assumption has led to the generally accept-
ed hypothesis that consumption of
isoflavonoids may prevent breast or
prostate cancer because these phytoestro-
gens compete with ovarian estradiol for
ER, thus reducing exposure to the more
active endogenous estrogenic hormones
(7,46,48). This line of reasoning was
offered as an explanation as to why
Japanese women, who have higher circulat-
ing levels ofless potent, short-acting estro-
gens such as estriol and estrone, have a
lower incidence ofbreast cancer than their
American counterparts (50). Although
these hypotheses regarding the protective
effects of the so-called weak or impeded
estrogens are logical, they are not necessari-
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Figure 8. Effects of orally administered coume-
strol on uterine growth in the rat. Ovariectomized
rats were treated with 100 pg/mL coumestrol dis-
solved in drinking water containing 2% Tween 80
(vehicle). Controls received water-Tween 80
vehicle and uterine wet and dry weights were
determined at the indicated times (0-96 hr) after
treatment. The uterine DNA content (not shown
in graph) after 72 hr of coumestrol treatment (242
pg/uterus) was not different from that measured
in uteri from controls (217 pg/uterus). Data are
means ± SEM.
ly supported by animal studies. It is well
documented that estriol and estradiol-17ci
are very weak estrogens incapable ofstimu-
lating cellular hyperplasia, when exposure
is acute (single injection). However, chron-
ic exposure to estriol or estradiol-17a via
multiple injection or subcutaneous implant
causes uterine cellular hypertrophy, hyper-
plasia, and mammary cancer in rodents in
a manner analogous to that achieved with
estradiol (28-31,51). This is a likely para-
digm for coumestrol, daidzein, and genis-
tein if their pharmacology and mechanism
ofaction are similar to those ofother short
acting estrogens (28-30,51).
Although some investigators have sug-
gested that coumestrol, daidzein, and other
related phytoestrogens may prevent cancer
because these compounds inhibit malig-
nant cell proliferation in vitro (52,53) and
dimethylbenz[a]anthracene (DMBA)
induction of mammary tumors in the rat
(54), these phytoestrogens do not inhibit
the growth of established DMBA-induced
mammary tumors (55), and their effects on
the growth ofother types of tumors in ani-
mals remains to be established. In fact,
there is a paucity of experimental data
directly demonstrating that phytoestrogens
inhibit tumor growth in vivo. On the other
hand, it is well documented that sustained
exposure to phytoestrogens during the
neonatal period is associated with persis-
tent vaginal cornification, cervico-vaginal
pegs and downgrowths, and uterine squa-
mous metaplasia, which mimics that
observed after exposure to diethylstibestrol
(56,57). These results demonstrate that
phytoestrogens may hyperestrogenize tar-
get tissues under certain experimental con-
ditions in vivo. Therefore, although it is
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Figure 9. Effe~Cotsofl cue roI}sl administra-
tion on cytosolic and nuclear estrogen receptor
(ER) and type 11 sites in the rat uterus. Uteri from
ovariectomnized rats treated with vehicle (con-
trols) or coumnestrol for 72 hr as described in
Figure 8 were assayed for cytosolic and nuclear
ER and type 11 sites by 13Hlestradiol exchange.
Results are expressed as binding sites/cell.
certainly possible that acute exposure to
phytoestrogens may block carcinogenic
insult to prevent cancer (46-48,54), these
compounds may also hyperestrogenize ER-
containing target tissues after chronic
exposure, and none ofthe parameters (dose
and duration of exposure) involved in
these response profiles have been adequate-
ly defined.
The present studies were performed to
more completely define the interactions of
isoflavonoids with ER and type II sites in
the ovariectomnized rat uterus and evaluate
subsequent effects on uterine growth and
DNA content after acute or sustained
exposure to these phytoestrogens. The
findings confirmed our hypothesis that
isoflavonoids bind to the ER with low
affinity and therefore should demonstrate
very little estrogenic activity when admin-
istered acutely. In fact, the apparent disso-
ciation constants of coumnestrol and
daidzein for rat uterine nuclear ER were
approximately 180 nM and 1000 nM,
respectively, whereas little competition was
obtained with genistein (Fig. 1). Based on
these binding affinities for ER, one has to
wonder whether endogenous levels of
either coumestrol or genistein will reach
concentrations capable of occupying ER
and eliciting estrogenic response under
normal physiological conditions. Although
we previously noted that some
isoflavonoids and lignans failed to compete
significantly for nuclear type II sites before
becoming insoluble in the binding assays
(8), we used dimethylsulfoxide to solubilize
these compounds in the present studies to
enhance their solubility in the aqueous
binding assay buffer. Under these condi-
tions counestrol and daidzein competed
for[3Hnestradiol binding to nuclear type II
sites and displayed much higher affinities
for this protein (Fig. 1). That coumestrol
and daidzein displayed much higher affini-
ties for nuclear type II sites (Kd 5-10 nM)
than for the ER suggests that type II sites
might be occupied in vivo at concentra-
tions where these compounds will not bind
to ER. This is currently being evaluated.
The ability of isoflavonoids to interact
with both the ER and nuclear type II sites
suggest that these compounds may display
mixed agonist/antagonist activities. At
lower concentrations (<100 nM) coume-
strol may occupy nuclear type II sites (Kd
10 nM) and inhibit cell proliferation, as we
have shown for luteolin and quercetin (8),
whereas at higher concentrations (>100
nM) coumestrol may occupy ER (Rd -180
nM), resulting in the stimulation ofcellu-
lar proliferation. This concept is consistent
with our observations that the binding of
the ER complex in the nucleus results in
the estrogen-induced dissociation of
MeHPLA from nuclear type II sites, and
similar events may occur after the binding
ofisoflavonoid-ER complexes in the nucle-
us as well (14,58). However, it is impor-
tant to consider that although supraphysio-
logical concentrations (pM) of coumestrol
stimulate ER-dependent reporter gene
transcription in MCF7 breast cancer cells
or HeLa cervical cancer cells in vitro
(59,60), whether endogenous levels of
coumestrol reach concentrations required
for ER (100-1000 nM) binding in vivo
under physiological conditions remains to
be resolved.
Although recent studies demonstrate
that oral administration of coumestrol
increased uterine wet and dry weight,
nuclear ER levels, and uterine progesterone
receptor content in intact, immature rats,
uterine DNA content was not determined
in these studies (15-17), and whether
coumestrol stimulated cellular hyperplasia
remains to be resolved. Therefore, even
though coumestrol appeared to behave as a
complete estrogen in these experiments,
the animals were dosed with the phytoe-
strogen over a number of days, and it is
possible that ovarian-derived estrogen con-
tributed to the observed stimulation of
uterine growth and progesterone receptor
content as these animals reached puberty.
The present studies using the immature,
ovariectomized rat support this contention.
Although coumestrol administration by
single or multiple injection (Figs. 2-4) or
orally in the drinking water (Figs. 7 and 8)
increased uterine wet and dry weights rela-
tive to control, even sustained exposure to
high doses of this phytoestrogen failed to
increase uterine DNA content, suggesting
that uterine hyperplasia was not observed.
This is a significant finding demonstrating
that increases in uterine wet and dry
weight are not always indicative of uterine
hyperplasia as reflected by a doubling in
DNA content (28,29). It is more likely
that the coumestrol-induced increase in
uterine wet and dry weight in our studies
in ovariectomized animals reflected
increases in water and protein content.
Studies by Yamazaki demonstrating that
the isoflavonoid ipriflavone is estrogenic in
intact, but not ovariectomized animals
(20) support our findings with coumestrol
and confirm the hypothesis that ovarian
estrogens contribute to the net estrogenic
response ofthe uterus to isoflavonoids.
Further evidence that coumestrol may
be an atypical estrogen is provided bystud-
ies where the effects of this phytoestrogen
on ER function were assessed. In two sepa-
rate experiments designed to evaluate the
temporal effects of coumestrol on ER
dynamics and compartmentalization in the
ovariectomized rat uterus, injection of 100
pg (or 500 pg; not shown) of coumestrol
failed to deplete cytosolic ER or cause
nuclear ER accumulation (Figs. 5 and 6)
even though increases in uterine wet and
dryweight were observed. These results are
in sharp contrast to the data in Figure 6
where injection of immature, ovariec-
tomized rats with estradiol resulted in the
classical cytosolic ER depletion and nuclear
ER accumulation and retention patterns
which precede estradiol stimulation of
uterine growth in immature (28,29) or
adult, ovariectomized rats (29-31,35).
Since sustained nuclear occupancy by the
ER-estrogen complex is generally thought
to be required for cellular hyperplasia and
DNA synthesis (28-31), it is not surpris-
ing that coumestrol failed to stimulate
uterine cellular hyperplasia (DNA content)
under these experimental conditions in
ovariectomized rats.
Even more surprising was the observa-
tion that subcutaneous injection (Figs. 5
and 6) or oral administration of coume-
strol (Fig. 9) increased cytosolic ER levels
two- to threefold without causing signifi-
cant cytosolic depletion and nuclear accu-
mulation of ER or induction of nuclear
type II sites, which are characteristic
responses to estrogenic hormone adminis-
tration (22,23,28). These latter two
nuclear events are typically correlated with
estrogenic stimulation of cellular DNA
synthesis and proliferation (28-30,35).
These findings also imply that coumestrol
may be an atypical estrogen which does
not modulate ERor type II site function in
a manner analogous to that of estradiol
(Figs. 6 and 9), estriol, or estradiol-17a
(28-31) in the ovariectomized rat uterus.
Consequently, although recent studies sug-
gest nuclear ER are elevated in coumestrol-
treated, intact, immature rats (15-17), this
ER could have been occupied by ovarian
estrogen and not necessarily coumestrol.
Although it is certainly possible that
much higher doses of coumestrol would
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stimulate true uterine growth in the pre-
sent studies, injection of500 pg ofcoume-
strol under the conditions described in
Figures 5 and 6 also failed to cause cytoso-
lic ER depletion and/or nuclear ER accu-
mulation and DNA synthesis (not shown).
Nevertheless, 500 pg ofcoumestrol stimu-
lated cytosolic ER in a manner similar to
that shown obtained with 100 pg of this
phytoestrogen (Fig 5). Therefore, increas-
ing the dose level of coumestrol fivefold
(-10 mg/kg bodyweight) failed to alter the
response profiles at these short times (1-3
days) after injection. Whether this increase
in cytosolic ER concentration after coume-
strol treatment reflects phytoestrogen-
induced ER activation, ER phosphoryla-
tion, and/or the stimulation of ER gene
transcription remains to be resolved
(61,62).
Regardless ofthe mechanism by which
coumestrol increases ER concentration in
the uterus, it appears that this isoflavonoid
may enhance the sensitivity of this target
tissue to estradiol. The data in Figure 10
demonstrate that coumestrol pretreatment
significantly shifted the dose-response
curve for estradiol, and it is likely that
coumestrol induction of cytosolic ER as
shown in Figures 5 and 6 was responsible
for this increased sensitivity of the uterus
to estradiol. Therefore, the mechanisms by
which phytoestrogens such as coumestrol,
daidzein, and genistein modulate estro-
genic response and uterine growth may be
much more complex than generally
thought and may involve binding to ER,
increasing the ER binding capacity of
estrogen target tissues such as the uterus
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Figure 10. Coumestrol effects on estradiol stimula-
tion of uterine growth in the rat. Adult, ovariec-
tomized rats were treated orally with vehicle (2%
Tween 80) or coumnestrol (250 pg/mL) in the drink-
ing water for 5 days before receiving three daily
subcutaneous injections of the indicated doses
(0.1-10 pg) of estradiol. Animals were sacrificed
24 hr after the last injection and uterine wet
weights were determined. Results are expressed
as the mearns ±. SEM and the resonseo to 1,5 and
vehicle ~ ~ Esrai control
by causing ER activation or phosphoryla-
tion (60,61) or by enhancing ovarian
release of estrogen. If this is the case, one
might anticipate that the observed estro-
genicity or antiestrogenicity of dietarily
derived phytoestrogens such as coumestrol
may be different in premenopausal and
postmenopausal women. This being the
case, it is difficult to speculate as to
whether phytoestrogens such as coume-
strol will prevent and/or protect against
cancer by competing with ovarian estro-
gens for ER as suggested (5,6) or whether
continuous consumption ofantiestrogenic
flavonoids such as luteolin and quercetin
which inhibit the growth ofa broad spec-
trum of rodent (8,9) and human cancers
in vitro and in vivo (10-13) will reduce
cancer incidence in humans by antago-
nism at the level ofthe type II site. Studies
designed to accurately define the estro-
genicity and antiestrogenicity of dietarily
derived isoflavonoids and flavonoids and
potential interactions with one another
and endogenous estrogens and androgens
in these experimental systems will be
required to adequately address these issues.
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"Mechanisms and Prevention of Environmentally Caused Cancers", a symposium presented
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environmentally-caused cancer and investigators focusing on preventing cancer development with
chemo-intervention strategies. Dr. Bruce Ames (University of California) will be the keynote speaker.
Other speakers include Dr. Eric Stanbridge (UC Irvine), Dr. Stephen Friend (Harvard), and Dr. Gary
Stoner (Ohio State University).
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